<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pharmaceutical Innovation Clusters - ByteSized Research</title>

    <!-- Retro Font -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Press+Start+2P&display=swap" rel="stylesheet">

    <link rel="stylesheet" href="css/styles.css">
</head>
<body>
    <!-- EJECT BUTTON -->
    <div class="eject-button-container">
        <button id="ejectButton" class="eject-button">
            <span class="eject-icon">‚óÑ</span> EJECT
        </button>
    </div>

    <!-- Header -->
    <header class="header">
        <div class="container">
            <h1>Pharmaceutical Innovation Clusters</h1>
            <p class="subtitle">Discovering temporal patterns in FDA drug approvals</p>
        </div>
    </header>

    <!-- Main Content -->
    <main class="main-content">
        <div class="container">

            <!-- Introduction Section -->
            <section class="intro-section">
                <div class="intro-card">
                    <h2>What Are Pharmaceutical Innovation Clusters?</h2>
                    <p>
                        History shows us that major pharmaceutical innovations don't happen randomly‚Äîthey cluster together in waves.
                        Two-thirds of all antibiotic types ever discovered emerged in a single 20-year window (1940s-1960s).
                        This analysis examines FDA drug approvals from 1939‚Äì2024 to identify these temporal patterns
                        and reveal disparities in therapeutic development.
                    </p>
                </div>
            </section>

            <!-- Statistics Section -->
            <section class="stats-section">
                <div class="stats-grid">
                    <div class="stat-card">
                        <div class="stat-number" id="total-innovations">---</div>
                        <div class="stat-label">FDA Drug Approvals</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-number" id="cluster-count">---</div>
                        <div class="stat-label">Cluster Periods</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-number" id="peak-decade">---</div>
                        <div class="stat-label">Peak Decade</div>
                    </div>
                </div>
            </section>

            <!-- Question Section -->
            <section class="question-section">
                <h2>Are Innovations Random?</h2>
                <p class="section-description">
                    History shows us that major pharmaceutical breakthroughs don't happen randomly‚Äîthey cluster together in waves.
                    Two-thirds of all antibiotic types ever discovered emerged in a single 20-year window (1940s-1960s).
                    But is this pattern statistically significant, or just coincidence?
                </p>
                <p class="section-description">
                    Let's examine the FDA approval timeline to see if any patterns emerge...
                </p>
            </section>

            <!-- Master Timeline Section -->
            <section class="timeline-section">
                <h2>üìä FDA Drug Approval Timeline</h2>
                <p class="section-description">
                    Each bar represents a decade of pharmaceutical approvals. Hover to see exact counts.
                </p>
                <div id="master-timeline" class="timeline-container">
                    <div class="loading">Loading timeline...</div>
                </div>
                <p class="transition-text">
                    The spikes are visually striking, but are they statistically significant or just random variation?
                </p>
            </section>

            <!-- Statistical Analysis Section -->
            <section class="stats-tests-section">
                <h2>üî¨ Statistical Analysis Results</h2>
                <p class="section-description">
                    Using the Coefficient of Variation and sliding window analysis, we can prove that pharmaceutical innovations cluster together rather than occurring randomly.
                </p>

                <div id="poisson-results" class="test-results-grid">
                    <div class="loading">Loading statistical tests...</div>
                </div>

                <p class="transition-text">
                    <strong>The verdict: These clusters are real.</strong> Two major innovation surges emerge from the data.
                    Let's explore what drove each unprecedented wave of pharmaceutical development...
                </p>
            </section>

            <!-- Drug Approval Clusters -->
            <section class="clusters-section">
                <h2>FDA Drug Approval Clusters</h2>
                <p class="section-description">
                    Periods of statistically significant spikes in pharmaceutical approvals
                </p>
                <div id="fda-cluster-list" class="cluster-list">
                    <div class="loading">Loading...</div>
                </div>
            </section>

            <!-- Pharmaceutical Insights Section -->
            <section class="unique-insights-section">
                <h2>üîç Pharmaceutical Insights</h2>
                <p class="section-description">
                    Now that we've identified the major innovation clusters, let's zoom out to examine the broader therapeutic landscape.
                    Which disease areas have attracted the most investment? Where are the innovation gaps?
                </p>

                <!-- Top Therapeutic Areas -->
                <div class="insight-container">
                    <h3>Top Therapeutic Areas by Approval Count</h3>
                    <p class="insight-intro">
                        Broad therapeutic categories ranked by total FDA drug approvals.
                        Shows which disease areas have attracted the most pharmaceutical investment.
                    </p>
                    <div id="top-therapeutic-areas">
                        <div class="loading">Loading therapeutic areas data...</div>
                    </div>
                </div>

                <!-- Emerging Drug Classes -->
                <div class="insight-container">
                    <h3>Emerging Drug Classes (Only 1 Drug Each)</h3>
                    <p class="insight-intro">
                        Cutting-edge pharmaceutical innovations where only a single drug has been approved.
                        These represent breakthrough therapies or novel mechanisms of action entering the market.
                    </p>
                    <div id="pharmaceutical-neglect">
                        <div class="loading">Loading drug class data...</div>
                    </div>
                </div>

                <!-- Therapeutic Trends -->
                <div class="insight-container">
                    <h3>Therapeutic Area Trends</h3>
                    <p class="insight-intro">
                        Which therapeutic areas have flourished, and which have been left behind?
                        Exploring the evolution of drug development across disease categories.
                    </p>
                    <div id="therapeutic-trends">
                        <div class="loading">Loading therapeutic trends data...</div>
                    </div>
                </div>

                <!-- Decade Breakdown: Generic vs Innovative -->
                <div class="insight-container">
                    <h3>The Generic Drug Revolution</h3>
                    <p class="insight-intro">
                        The 1980s boom wasn't just about innovation‚Äîit was fueled by the rise of generic drugs.
                        See how the balance between innovative and generic drugs shifted over time.
                    </p>
                    <div id="decade-breakdown-chart">
                        <div class="loading">Loading decade breakdown data...</div>
                    </div>
                </div>
            </section>

            <!-- Methodology Section -->
            <section class="methodology-section">
                <div class="container">
                    <h2>Methodology</h2>
                    <div class="methodology-grid">
                        <div class="method-card">
                            <h3>Data Sources</h3>
                            <ul>
                                <li>FDA Orange Book API (drug approvals, 1939-2024)</li>
                                <li>71,149 total drug approvals analyzed</li>
                                <li>Classification via FDA pharmacological classes + indication fields</li>
                            </ul>
                        </div>
                        <div class="method-card">
                            <h3>Clustering Method</h3>
                            <ul>
                                <li>Statistical threshold: >2œÉ above mean</li>
                                <li>Minimum cluster size: 3 consecutive years</li>
                                <li>Identifies periods of unusual approval density</li>
                            </ul>
                        </div>
                    </div>
                    <div class="disclaimer-card">
                        <h3>Research Context</h3>
                        <p>
                            This analysis reveals temporal patterns in pharmaceutical innovation and therapeutic neglect
                            but does not establish causality. Multiple factors‚Äîeconomic incentives, regulatory changes,
                            disease prevalence, research funding, and market size‚Äîmay contribute to these patterns.
                        </p>
                    </div>
                    <div class="disclaimer-card">
                        <h3>Classification Methodology & Limitations</h3>
                        <p><strong>Classification Approach:</strong></p>
                        <ul style="margin-bottom: 15px;">
                            <li><strong>Data Source:</strong> FDA pharmacological class fields (EPC & MOA) with 345 unique classes</li>
                            <li><strong>Simplification:</strong> Technical FDA terms converted to plain language (e.g., "Programmed Death Receptor-1 Blocking Antibody" ‚Üí "PD-1 Inhibitors")</li>
                            <li><strong>Secondary data:</strong> FDA indication and usage fields for context</li>
                            <li><strong>Fallback:</strong> Keyword matching on generic drug names when FDA classification unavailable</li>
                            <li><strong>No assumptions:</strong> Using actual FDA classifications, not manually-created therapeutic buckets</li>
                        </ul>
                        <p><strong>Known Limitations:</strong></p>
                        <ul>
                            <li><strong>Combination drugs:</strong> Drugs with multiple therapeutic uses are assigned to a single primary pharmacological class</li>
                            <li><strong>Missing data:</strong> Older drugs (pre-1980s) may lack complete pharmacological classification in FDA records (~86% unclassified)</li>
                            <li><strong>Off-label use:</strong> Drugs approved for one condition but widely used for another are classified by their FDA-approved indication only</li>
                            <li><strong>Emerging categories:</strong> Gene therapies and novel modalities are classified under their pharmacological mechanism, not disease</li>
                            <li><strong>Data completeness:</strong> Classification accuracy improves for recent approvals (2000+) due to more complete FDA metadata</li>
                        </ul>
                        <p style="margin-top: 15px;"><em>Note: Drug counts represent FDA-approved pharmacological classes, not therapeutic impact. Market size, clinical significance, and innovation value may not correlate with approval counts. A class with 1 drug (e.g., "TYK2 Inhibitors") may represent groundbreaking innovation, while classes with 800+ drugs may be saturated markets.</em></p>
                    </div>
                </div>
            </section>

        </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>Data source: FDA Orange Book API (1939-2024)</p>
            <p>Analysis method: Statistical temporal clustering | Therapeutic area classification</p>
        </div>
    </footer>

    <!-- D3.js for interactive visualizations -->
    <script src="https://d3js.org/d3.v7.min.js"></script>

    <script src="js/app.js"></script>
    <script src="js/statistical-viz.js"></script>
    <script src="js/timeline-viz.js"></script>
    <script src="js/unique-insights.js"></script>
    <script src="js/therapeutic-peaks-viz.js"></script>
    <script src="js/decade-breakdown-viz.js"></script>
    <script src="js/therapeutic-timeline.js"></script>

    <!-- Eject Button Logic -->
    <script>
        document.getElementById('ejectButton').addEventListener('click', function() {
            this.style.transform = 'scale(0.95)';
            setTimeout(() => {
                this.style.transform = '';
            }, 100);
            setTimeout(() => {
                window.location.href = '/';
            }, 200);
        });
    </script>
</body>
</html>
